DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts
Transforming growth factor beta (TGF-β) signalling has become an attractive therapeutic target due to its pro-tumorigenic actions on epithelial cells and its immunosuppressive effects in the tumour microenvironment. In intrahepatic cholangiocarcinoma (iCCA), a highly aggressive malignancy of the biliary tract with poor prognosis, the latest clinical trials using TGF-β inhibitors have failed indicating that the specific actions carried out by TGF-β in iCCA are yet not well delineated. Here, we show that TGF-β signalling is highly active in iCCA and exerts a prominent suppressor effect on tumour cell lines and organoids established from iCCA metastases biopsies, that relies on a functional canonical SMAD2/3/4 signalling. Thus, TGF-β inhibitors promote, instead of inhibiting, tumour cell growth. In this context, a promising strategy is to target intracellular proteins downstream the TGF-β receptors accounting only for TGF-β pro-tumorigenic actions. NADPH oxidase 4 (NOX4), a downstream mediator of the TGF-β signalling pathway, is strictly expressed in cancer-associated fibroblasts (CAF) of iCCA and acts in concert with NOX1 to regulate CAF functions. Use of a dual NOX4/NOX1 inhibitor impaired CAF actions and reduced tumour growth in vitro and in two different in vivo iCCA experimental models. Collectively, our findings reveal an actionable way to specifically target TGF-β pro-tumorigenic actions in CAF from iCCA without undesirable side effects on tumour cells, suggesting a potentially bright future for dual NOX4/NOX1 inhibitors in the clinics, alone or in combination with other therapies., This work was supported by (i) Spanish Association for Cancer Research (AECC), Spain, grant #PRYGN211279FABR, to I.F.; (ii) Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers #RTI2018-094079-B-100, #RTC2019-007125-1, to I.F.; #PID2019-108651RJ-I00, PID2022-141984OB-I00 and RYC2021-034121-I, to J.V. J.V. was funded by AEI, MICIN, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and “Ramon y Cajal” program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. C.C. is supported by Inserm, Université de Rennes, Ligue Contre le Cancer (R23037NN), INCa (EU TRANSCAN23-002-2023-129, INCa_18688, R21251ND), ITMO Cancer of AVIESAN within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm (C18007NS, C20013NS, C20014NS), the French Ministry of Health and the French National Cancer Institute (PRT-K20-136). T.V.T. was supported by grants from the Spanish Ministry of Science, Innovation and University (PID2019-108008RJ-I00, PID2023-146827OB-I00), Fundació La Marató TV3 (201931-31), and “Ramon y Cajal” program (RYC2020-029098-I). L.F. received financial support from the “Ligue contre le cancer” (RS24/75-62) and from ITMO Cancer of Aviesan on funds administered by Inserm (C21044DS/ ASC21044DSA). S.A. is supported by PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312* and Ramon y Cajal program RYC2022-036321-I. *, Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-094079-B-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTC2019-007125-1
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108651RJ-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-141984OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108651RJ-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108008RJ-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-146827OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-124694OA-I00
DOI: http://hdl.handle.net/10261/425823, https://api.elsevier.com/content/abstract/scopus_id/105013462453
HANDLE: http://hdl.handle.net/10261/425823, https://api.elsevier.com/content/abstract/scopus_id/105013462453